Company Overview
Rain Oncology is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers.
Stock Snapshot
NASDAQ GS: RAIN Rain Oncology (Common Stock)
Price
Change
Volume
Data provided by Refinitiv. Minimum 15 minutes delayed.